# Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India

> **NCT00289172** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 360 (—)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Live attenuated human rotavirus vaccine

## Key facts

- **NCT ID:** NCT00289172
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-10
- **Primary completion:** —
- **Final completion:** 2006-09-08
- **Target enrollment:** 360 (—)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289172, "Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00289172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*